REGISTER
OCC 2026 | China’s One-Time Ultrasound Therapy for Hypertension
Prof. Xiangqing Kong reflects on China’s move from following global innovation to developing original cardiovascular solutions. He discusses the focused ultrasound device for hypertension, its precision requirements, and early randomized trial data showing reductions in 24-hour ambulatory systolic blood pressure.

In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts from China and Australia gather to discuss “Hypertension · Cornerstone Chapter — From Blood Pressure Management to Root-Cause Innovation”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-hosted by Prof. Dongying Zhang, The First Affiliated Hospital of Chongqing Medical University. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Xiangqing Kong, The First Affiliated Hospital with Nanjing Medical University; and Prof. Alberto P. Avolio, Macquarie University, Australia.

The roundtable focuses on how hypertension care may evolve from numerical blood pressure control toward mechanism-based and precision-oriented management. The experts discuss the limitations of lifelong medication, the low global control rate of hypertension, central nervous system regulation, perirenal adipose tissue as a potential therapeutic target, arterial stiffness and hemodynamic mechanisms, cuffless and wearable blood pressure monitoring, clinical validation standards, and the future role of Chinese innovation in reshaping global hypertension treatment.

In this segment, Prof. Xiangqing Kong reflects on China’s path from following global cardiovascular innovation to contributing original solutions. Drawing on his previous experience developing a ventricular septal defect closure device adopted in 87 countries and regions, he explains how long-term engineering refinement and repeated validation helped turn a challenging anatomical problem into a globally recognized device solution.

Prof. Kong then discusses the development of his focused ultrasound device for hypertension, emphasizing the precision required to target the perirenal region while avoiding kidney injury and surrounding tissue damage. He shares early randomized clinical trial experience in China, where a one-time non-invasive intervention showed reductions in 24-hour ambulatory systolic blood pressure, with a more pronounced effect observed during nighttime monitoring.

0
0
Loading